India, Hyderabad, 5 th May, 2017: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, announced today that it has received the approval for the generic version of ‘Sofosbuvir+Velpatasvir’ combination from Drugs Controller General of India. The product will be marketed and distributed under the brand name ‘Velasof’ in India by Hetero Healthcare Ltd.
Sofosbuvir+Velpatasvir is a two-drug fixed dose combination product that contains 400mg of Sofosbuvir and 100mg of Velpatasvir in a single tablet. This fixed-dose combination is the generic version of Gilead’s brand Epclusa ®, approved by US FDA for the treatment of patients with chronic hepatitis C genotype 1 to 6.
This product will be launched under the non-exclusive licensing agreement with Gilead Sciences, Inc., which allows to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Established by Dr. B.P.S. Reddy in 1993, Hetero is in the business of development, manufacturing and marketing of drug intermediates, active pharmaceutical ingredients (APIs), and finished dosages.
Hetero has over 25 state-of-the-art manufacturing facilities which has been approved by various regulatory authorities like US FDA, EU, TGA – Australia, MCC – South Africa among others. With more than 200 products in its portfolio across various therapeutic areas, Hetero has a strong global presence in 120+ countries. The company focuses on making affordable medicines accessible to patients worldwide. For more information on Hetero, please visit www.heteroworld.com.
Head – Corporate Communications
Hetero Labs Limited, India
Mobile: +91 9989626541/ +91 9833836185